Asset profile
Brexpiprazole (Rexulti)
Small molecule
Evidence outlook
Approved: Alzheimer's Disease, Major Depressive Disorder, Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
180 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 174 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Brexpiprazole (Rexulti): this drug | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| ITI-1284 | Phase 2 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Brexpiprazole Long-Acting Injection (Kelun) | Phase 1 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | ||
| Dexmedetomidine (Igalmi) | Approved | — | — | ||
| Dexmedetomidine (Igalmi) | Approved | Small molecule | Alpha-2 adrenergic receptor (agonist) | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA |
…and 165 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
2028 (1)
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.